News and Events

Latest News

Stay up to date on Relief activities

Here you will find latest news, upcoming events and interviews.

Corporate News

Archive

Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit

14 January 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Comments on Lawsuit Filed Against It by NeuroRx

12 January 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner has announced that it has Submitted an Application to the FDA seeking Emergency Use Authorization for Aviptadil to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies

06 January 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent for Stable Compositions of Aviptadil Suitable for Human Use

04 January 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA

03 January 2022 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner has Announced it has Filed a Breakthrough Therapy Designation Request for Aviptadil in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies

30 December 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Reports the Successful Conclusion of the Patent Examination Procedure for the Patent Application Entitled, “Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis”

28 December 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

16 December 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner has Announced a New, Favorable Safety Report for Aviptadil in the NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

15 December 2021 | Ad Hoc Announcement pursuant to Art. 53 LR
Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil

10 December 2021 | Ad Hoc Announcement pursuant to Art. 53 LR

Events and Presentations

H.C. Wainwright BioConnect Conference - January 10 - 13, 2022

Monday, January 10, 2022

7:00am EST

Listen to Webcast

Scientific References

RLF-100™

Media Contact

For media inquiries contact:

Rx Communication Group
Michael Miller
Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel.: 917.633.6086

Latest News

Corporate News

Archive

Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit

Relief Comments on Lawsuit Filed Against It by NeuroRx

Relief Reports that its U.S. Collaboration Partner has announced that it has Submitted an Application to the FDA seeking Emergency Use Authorization for Aviptadil to Treat Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies

Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent for Stable Compositions of Aviptadil Suitable for Human Use

Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA

Relief Reports that its U.S. Collaboration Partner has Announced it has Filed a Breakthrough Therapy Designation Request for Aviptadil in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies

Relief Therapeutics Reports the Successful Conclusion of the Patent Examination Procedure for the Patent Application Entitled, “Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis”

Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

Relief Reports that its U.S. Collaboration Partner has Announced a New, Favorable Safety Report for Aviptadil in the NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil

Events and Presentations

H.C. Wainwright BioConnect Conference - January 10 - 13, 2022

Scientific References

RLF-100™

Media Contact

Company

Pipeline

Investor Relations

News and Events